Application of complement component in preparation of psoriasis screening and diagnosis kit
By detecting complement components in nail tissue, a psoriasis diagnostic kit was established. Utilizing a combined diagnostic model of complement components such as C1R, C2, C1QC, C7, C6, C9, C4A, and C1QB, the accuracy problem of psoriasis screening and diagnosis was solved, achieving highly specific and non-invasive detection.
Patent Information
- Application Number
- CN202511285501.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-10
- Publication Date
- 2026-01-23
AI Technical Summary
Existing technologies make it difficult to efficiently screen and diagnose psoriasis using a single indicator, especially psoriasis and psoriatic arthritis. Furthermore, traditional testing methods have significant cross-reactivity, which affects diagnostic accuracy.
Complement components such as C1R, C2, C1QC, C7, C6, C9, C4A, and C1QB are used as biomarkers. The content of complement components in nail tissue is detected by proteomics technology to establish a combined diagnostic model and provide a diagnostic kit for psoriasis.
It improves the accuracy of psoriasis screening and diagnosis, reduces cross-reactions with other autoimmune diseases, and enables non-invasive or minimally invasive testing, making it suitable for early screening, differential diagnosis, and efficacy monitoring.
Smart Images

Figure CN121385314A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of diagnostic kits, in particular, it provides a new method and kit for early screening and diagnosis of psoriasis and psoriatic arthritis by detecting the content of complement components (C1R, C2, C1QC, C7, C6, C9, C4A, C1QB) in nails. BACKGROUND
[0002] Psoriasis (PSO) is a common refractory and inflammatory skin disease, which affects 1-3% of the global population and is listed as one of the "top ten diseases in the 20th century" by the World Health Organization. The itching and scaling of psoriasis often cause patients to develop depression and anxiety, and it can also involve multiple sites, combined with metabolic diseases, autoimmune diseases and other systemic diseases.
[0003] Small molecule drugs, biological agents, traditional Chinese medicines and other combined systemic treatments are used in clinical practice for psoriasis. Some patients develop immune drift after taking drugs, accompanied by different symptoms of chronic inflammatory skin diseases, which weakens the efficacy. Early screening and diagnosis can help to intervene and control the progression of PSO and its comorbidities. Since PSO has different types, the expression of biomarkers differs greatly among them, making it difficult to use a single indicator for screening and diagnosis. Therefore, accurate screening, diagnosis and assessment of the severity of skin lesions are of great significance to ensure efficacy and improve quality of life.
[0004] In recent years, with the in-depth study of the pathological mechanism of psoriasis, it has been found that the expression of certain complement components is significantly up-regulated in patients with psoriasis and psoriatic arthritis (PsA), providing a new idea for early screening and diagnosis of psoriasis. Through high-throughput analysis methods of proteomics technology, it can be used as a new biomarker combination to improve the accuracy of diagnosis of different types of psoriasis and overcome the limitations of traditional detection methods, providing more reliable biomarkers and treatment basis for clinical practice.
[0005] Complement molecules are an important family of proteins in the immune system, widely involved in innate immune defense, inflammatory response, pathogen clearance and immune regulation, which can be used as potential biomarkers for disease screening, diagnosis and prognosis evaluation, and has been widely used in systemic lupus erythematosus, sepsis, tumor and other diseases. SUMMARY
[0006] The purpose of the present application is to provide a complement component for use in a psoriasis screening and diagnosis kit, to develop a new biomarker combination and to improve the accuracy of psoriasis screening and diagnosis.
[0007] In a first aspect, the present application provides a use of complement components as diagnostic markers in the preparation of a diagnostic kit for psoriasis, wherein the complement components are selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
[0008] The present application has found that C1R, C2, C1QC, C7, C6, C9, C4A and C1QB are specifically expressed in psoriasis and psoriatic arthritis, and the most significantly up-regulated are C4A, C1QC and C9.
[0009] In a second aspect, the present application provides a use of reagents for detecting the content of complement components in tissues in the preparation of a diagnostic kit for psoriasis, wherein the complement components are selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
[0010] Further, the tissue is nail tissue.
[0011] Further, the nail tissue is the tissue 1-2 mm outside the free edge of the nail plate (located at the end of the nail body, between the edge of the nail bed and the finger core).
[0012] Further, the psoriasis is psoriatic arthritis.
[0013] Further, the complement components are detected alone or in combination.
[0014] Further, when the combination detection is used, the diagnostic model is:
[0015]
[0016] When LogitP>0, i.e. P>0.5, it is diagnosed as psoriasis.
[0017] In a third aspect, the present application provides a diagnostic kit for psoriasis, wherein the kit comprises reagents for detecting the content of complement components in nail tissue, and the complement components are selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
[0018] Further, the reagents for detecting the content of complement components in nail tissue are reagents for detecting the content of complement components in nail tissue by proteomics.
[0019] In a fourth aspect, the present application provides a diagnostic model for psoriasis, and the calculation formula of the diagnostic model is as follows:
[0020]
[0021] When LogitP>0, i.e. P>0.5, it is diagnosed as psoriasis.
[0022] The present application has the advantages of:
[0023] 1. High specificity: complement components are specifically expressed in psoriasis, reducing cross-reactions with other autoimmune diseases;
[0024] 2. Non-invasive / minimally invasive: can be detected by nail samples, avoiding the invasive procedure of skin biopsy;
[0025] 3. Wide application: suitable for early screening of PSO, differential diagnosis of PSA, and dynamic monitoring of therapeutic effect. BRIEF DESCRIPTION OF DRAWINGS
[0026] Figure 1: Protein expression levels of complement components in PSO, PSA and healthy control groups.
[0027] Figure 2: ROC curve of complement combination diagnosis of PSO (A) and PSA (B).
[0028] Figure 3: Correlation scatter plot of C1R expression and PASI score of PSO patients.
[0029] Figure 4 : ROC curve results of complement component indicators in combination. DETAILED DESCRIPTION
[0030] The specific embodiments provided by the present application will be described in detail below in conjunction with the examples.
[0031] Example 1:
[0032] 1. Experimental materials and methods
[0033] (1) Sample collection and grouping
[0034] Sample source: 13 cases of psoriasis (PSO) patients, 13 cases of psoriatic arthritis (PSA) patients, and 13 cases of age and gender matched healthy controls (HC).
[0035] Sample type: Collect the 1-2 mm part of the nail plate free line (located at the end of the nail body, which is the edge connecting the nail bed and the finger core and the nail cover) of the subject, and store it at -80℃ to avoid repeated freezing and thawing.
[0036] Clinical evaluation: PASI score of PSO and PSA patients.
[0037] (2) Non-targeted proteomics detection
[0038] Sample preparation: After cutting, total protein was extracted with lysis buffer (8 M urea, 2% SDS, 50 mM Tris-HCl, pH 8.0).
[0039] Protein quantification: BCA method (Pierce™ BCA Protein Assay Kit) was used to determine the concentration, which was adjusted to 1 μg / μL.
[0040] Mass spectrometry analysis:
[0041] Technology: Liquid chromatography-tandem mass spectrometry (LC-MS / MS) based on discovery non-targeting strategy to screen differential proteins.
[0042] Chromatographic conditions: Reversed-phase C18 column (2.1 × 150 mm, 1.7 μm), mobile phase A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile. Gradient: 0-120 min, B phase from 5% linearly increased to 95%.
[0043] Mass spectrometry parameters: ESI ion source (Thermo Q Exactive HF), positive ion mode, full scan range m / z 350-1800, resolution 70,000; data-dependent acquisition (DDA), Top 20 MS / MS.
[0044] Data processing: MaxQuant (v2.0.3) was used to analyze the data and align the human UniProt database (2023 version). Differential protein screening: one-way ANOVA, FDR < 0.05, differential fold (Fold Change) > 2.0.
[0045] (3) Targeted proteomics verification
[0046] Based on the target: Based on the non-targeting results, the screened complement components were verified by multiple reaction monitoring (MRM) targeted quantification.
[0047] Sample preparation: The same as the non-targeting method.
[0048] Mass spectrometry analysis:
[0049] Technology: LC-MRM mass spectrometry (Agilent 6495C).
[0050] Chromatographic conditions: HILIC column (2.1 × 100 mm, 1.8 μm), mobile phase A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile. Gradient: 0-10 min, B phase from 5% to 40%.
[0051] Mass spectrometry parameters: ESI ion source, positive ion mode; monitor each complement-specific peptide ion pair (e.g. C1R peptide m / z 556.3→639.4) with collision energy optimized to 20-35 eV.
[0052] Data processing: Skyline (v22.1) quantification, with stable isotope-labeled peptides (SIS, JPT Peptides) as internal references, and relative expression calculated after normalization.
[0053] (4) Statistical analysis
[0054] Data analysis was performed using R (4.2.1) version.
[0055] Untargeted metabolomics results: One-way ANOVA was used for inter-group comparison, and box plots were visualized using the ggplot2 package.
[0056] ROC curve analysis: A diagnostic model was constructed for the combination of complement components, and the area under the curve (AUC), sensitivity, and specificity were calculated to determine the optimal diagnostic threshold. ROC analysis was performed using the pROC package, and the results were visualized using ggplot2.
[0057] Correlation analysis: Spearman correlation analysis was used to assess the correlation between the expression of complement components and PASI scores.
[0058] 2. Experimental results
[0059] (1) Differences in expression of complement components in nails
[0060] Compared with the healthy control group, the protein expression levels of C1R, C2, C1QC, C7, C6, C9, C4A, and C1QB in the nails of PSO and PSA patients were significantly increased (P<0.01, Figure 1 ). Among them, C4A, C1QC, and C9 were most significantly upregulated.
[0061] Inter-group comparison: The expression levels of C1R and C2 in PSA patients were significantly higher than those in PSO patients (P<0.05), suggesting that they may be related to the severity of joint inflammation.
[0062] (2) Diagnostic performance of complement combinations
[0063] Individual ROC curve analysis of each complement component showed (see Figure 2), C1R had the highest diagnostic efficiency for psoriasis (PSO) with an area under the curve (AUC) of 0.929 (95% CI: 0.843-1.000), followed by C2 (AUC=0.917, 95%CI: 0.832-1.000); C1QC (AUC=0.873), C4A (AUC=0.870) and C6 (AUC=0.852) had moderate diagnostic efficiency, while C7 (AUC=0.796), C9 (AUC=0.822) and C1QB (AUC=0.781) had relatively lower AUC values but still higher than 0.7, suggesting that they had certain predictive value for PSO.
[0064] (3) Correlation of complement expression with disease severity
[0065] In PSO and PSA patients, the expression level of C1R was positively correlated with PASI score (r=0.68, 0.72, 0.65, all P<0.001, Figure 3), suggesting that its expression level could reflect the activity of skin inflammation.
[0066] Example 2:
[0067] A combined diagnostic model of C1R, C2, C1QC, C7, C6, C9, C4A and C1QB indicators was established by logistic regression:
[0068]
[0069] When LogitP>0, i.e. P>0.5, it was diagnosed as psoriasis.
[0070] ROC curve analysis of the combination of C1R, C2, C1QC, C7, C6, C9, C4A and C1QB indicators showed (see Figure 4 ), the area under the curve (AUC) was 0.982 (95% CI: 0.952, 1), and the predictive efficiency was higher than that of a single indicator.
[0071] Example 3:
[0072] The marker of the application in the clinical diagnosis steps:
[0073] 1) Collect 1-2 mm of tissue from the lateral side of the free edge of the nail plate (located at the end of the nail body, between the nail bed and the finger core);
[0074] 2) Detect the content of complement components C1R, C2, C1QC, C7, C6, C9, C4A or C1QB in the nail tissue by proteomics;
[0075] 3) The best diagnostic concentration threshold of each marker and its diagnostic direction among the eight complement system markers analyzed are as follows: if the concentration of C1QC is ≥405705.33, C2 is ≥29567.11, C7 is ≥38150.33, C6 is ≥29521.24, C9 is ≥143600.16, C4A is ≥703767.76, C1R is ≥26284.54 or C1QB is ≥37827.13, then the diagnosis is psoriasis; otherwise, if the concentration of each marker is lower than the above threshold, then the diagnosis is healthy control. See Table 1 for specific information.
[0076] Table 1. Summary of diagnostic performance and best threshold of complement system markers
[0077]
[0078] Example 4:
[0079] The joint diagnostic model of the present application in the clinical diagnosis step:
[0080] 1) Collect the sample from the free edge of the nail plate (located at the end of the nail body, between the nail bed and the finger core) 1-2 mm of tissue on the lateral side;
[0081] 2) Detect the content of complement components selected from C1R, C2, C1QC, C7, C6, C9, C4A and C1QB in the nail tissue by proteomics;
[0082] 3) Calculate LogitP by the joint diagnostic model:
[0083]
[0084] When LogitP > 0, i.e. P > 0.5, the diagnosis is psoriasis.
[0085] The above has specifically described the preferred embodiments of the present application, but the present application is not limited to the embodiments described above, and those skilled in the art can make various equivalent modifications or replacements without departing from the spirit of the present application. These equivalent modifications or replacements are all included in the scope defined by the claims of the present application.
Claims
1. Use of a complement component as a diagnostic marker in the manufacture of a diagnostic kit for psoriasis, characterized in that, The complement component is selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
2. Use of reagents for detecting the content of complement components in tissues for the preparation of a diagnostic kit for psoriasis, characterized in that, The complement component is selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
3. Use of the reagent for detecting the content of complement components in tissues according to claim 2 for the preparation of a diagnostic kit for psoriasis, characterized in that, The tissue is nail tissue.
4. Use of the reagent for detecting the content of complement components in tissues according to claim 3 for the preparation of a diagnostic kit for psoriasis, characterized in that, The nail tissue is the tissue of 1-2 mm outside the free line of the nail plate.
5. Use of the reagent for detecting the content of complement components in tissues according to claim 2 for the preparation of a diagnostic kit for psoriasis, characterized in that, The psoriasis is psoriatic arthritis.
6. Use of the reagent for detecting the content of complement components in tissues according to claim 2 for the preparation of a diagnostic kit for psoriasis, characterized in that, The complement component is detected alone or in combination.
7. Use of the reagent for detecting the content of complement components in tissues according to claim 2 for the preparation of a diagnostic kit for psoriasis, characterized in that, When LogitP>0, i.e. P>0.5, the diagnosis is psoriasis. The kit comprises reagents for detecting the content of complement components in nail tissue, wherein the complement component is selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB.
8. A psoriasis diagnostic kit, characterized by, The reagent for detecting the content of complement components in nail tissue is a reagent for detecting the content of complement components in nail tissue by proteomics.
9. The psoriasis diagnostic kit according to claim 7, characterized in that, The calculation formula of the psoriasis diagnosis model is as follows:
10. A psoriasis diagnostic model characterized by, When LogitP>0, i.e. P>0.5, the diagnosis is psoriasis.
